MariMed Reports Modest Revenue Growth, Sixth Year of Positive Adjusted EBITDA in FY25
MRMD sits 19% above its 52-week low of $0.067 on light trading volume (0.3× avg).
Summary
MariMed Inc. announced its Q4 and full-year 2025 financial results, reporting a modest revenue increase to $159.8 million for the year, up from $157.7 million in 2024. The company achieved its sixth consecutive year of positive Adjusted EBITDA, reaching $16.9 million, though this was a decrease from $19.3 million in the prior year. GAAP net loss widened to $14.5 million for the full year, compared to a $12.4 million loss in 2024. The report also highlighted the previously announced successful restructuring of its Series B obligation, extending its maturity by 4.6 years, which contributes to a strengthened balance sheet. These mixed results provide a critical update on the company's performance in a competitive cannabis market, demonstrating revenue resilience but also challenges in profitability. Traders will be watching for further updates on the company's strategic growth drivers, including adult-use sales in Delaware, brand distribution in Maine, and the planned dispensary opening in Ohio, to assess future margin and earnings improvement.
At the time of this announcement, MRMD was trading at $0.08 on OTC in the Trade & Services sector, with a market capitalization of approximately $31.4M. The 52-week trading range was $0.07 to $0.23. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.